The effects of Maraviroc on liver fibrosis in HIV/HCV co‐infected patients

• DOI: 10.7448/ias.17.4.19643
• Publication Date: 2014-11-03T08:30:34Z
• Authors: Enrique Ortega Go...; Vicente Boix; Miguel Garcia Del...; Jose Lopez Aldeguer; Joaquin Portilla; Marta Montero; Emilio Ballester ...; Vicente Abril; Felix Gutierrez; Carlos Minguez; Josefa Galindo; Concepcion Benirto; Magdalena Garcia ...; Livia Giner; Purificacion Rubio; Jorge Uso; Giovanna Llerena
• Keywords: Maraviroc; CCR5 receptor antagonist; Hepatic fibrosis

The fibrogenesis analysis in quimeric CCR1 and CCR5 mice revealed that mediates its pro-fibrogenic effects hepatic cells promoting stellate cells. blockage of co-receptors could preserve the progression fibrosis HIV/HCV co-infected patients.To evaluate beneficial on patients are antiretroviral therapy (ART) with co-receptor antagonists.A multicentre, retrospective pilot study evaluation at mid- long-term by non-invasive methods a cohort Valencian Community (Spain) received ART antagonist. cut-off points serum marker tests were: AST to Platelet Ratio Index (APRI)<0.5 (F0-F1); >1.5 F2; >2 Cirrhosis Forns Index<4.2 excludes fibrosis; >6.9>F2 fibrosis. Inclusion criteria was established for antagonists had no previous history interferon ribavirin treatment or those who were null-responders antagonist year. Patients HBV infection excluded.A total 71 male (69%) reported. A CD4 nadir <100 cells/uL observed 42% 62% (44/71) basal level >350 cells/uL. According genotypes, 50% G-1a, 14% G-1b, 11% G-3 25% G-4. median duration Maraviroc (MVC) following: 45% took it over year, 41% two years three years. Before starting MVC, we an initial F0-F1 49% patients, F2-F3 24% F4 27%. medium follow-up 18.45 months. Progression higher five 11 improved least one stage others stable time. There 38 taking MVC years, 27 this group (59.38%) did not modify their fibrosis, 3 (11%) progressed 8 (29.62%) showed regression liver stage.The data above shows benefit expressed tropism. prolong (over years) has better effect